Deep Genomics, a Canada-based genetic medicine developer backed by media company Bloomberg, received $13m on Monday in a series A round led by venture capital firm Khosla Ventures.
VC firm True Ventures also participated in the round, having previously invested in Deep Genomics’ $3.8m seed round in late 2015 together with Bloomberg’s corporate venturing arm, Bloomberg Beta, and unnamed angel investors.
Founded in 2015, Deep Genomics is looking to develop genetic therapies based on its artificial intelligence-led technology platform. It is currently working on a project that will hopefully generate a 1,000-strong library of compounds capable of manipulating cell biology.
VC fund Eleven Two Capital was not named among Deep Genomics’ seed investors at the time of the round but lists the startup as one of its portfolio companies. The series A capital will be used to increase the number of scientific experts at the company.